Clinical Study on Warming-Needle Moxibustion Combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for Inhalation for COPD in Stable Stage
Abstract:Objective:To observe the clinical effect of warming-needle moxibustion combined with salmeterol xinafoate and fluticasone propionate powder for inhalation for patients with chronic obstructive pulmonary disease(COPD) in stable stage,and its effect on quality of life as well as the heart function and the lung function. Methods:A total of 97 cases of patients with COPD in stable stage were randomly divided into the observation group and the control group,49 and 48 cases in each group respectively. The control group was given salmeterol xinafoate and fluticasone propionate powder for inhalation,and the observation group was additionally given warming-needle moxibustion based on the treatment of the control group. Both groups were treated for eight weeks. The clinical effect,the heart function[left ventricular end diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF), 6- minute walking test(6MWT)], the lung function [forced expiratory volume in the first second(FEV1),the ratio of FEV1 to forced vital capacity(FEV1/FVC),the percentage of predicated value of FEV1(FEV1% )], quality of life [the score of COPD Assessment Test(CAT)], and Chinese medicine syndrome score were compared between the two groups. The incidence of adverse reactions during treatment was observed. Results: The total effective rate was 93.88% in the observation group, and 79.17% in the control group, the difference being significant(P<0.05). After treatment,the scores of cough,expectoration,torpid intake,abdominal distension,shortness of breath,oppression in the chest,gasping,and spontaneous sweating in the two groups were decreased when compared with those before treatment(P<0.05),and each syndrome score in the observation group was lower than that in the control group(P<0.05). After treatment,LVEDD in the two groups were decreased when compared with those before treatment(P< 0.05),and LVEE,6MWT,FEV1,FEV1/FVC,and FEV1% were increased(P<0.05),and the improvement in the study group was more significant than that in the control group(P<0.05). After treatment, the scores of CAT in the two groups were decreased when compared with those before treatment(P<0.05),and the score in the observation group was lower than that in the control group(P<0.05). During treatment,no adverse events including local hematoma,scald,and infection occurred in the two groups. Conclusion: The therapy of warming- needle moxibustion combined with salmeterol xinafoate and fluticasone propionate powder for inhalation has a significant curative effect in the treatment of patients with COPD in stable stage,which can effectively relieve their clinical symptoms,improve the heart function and the lung function,and enhance quality of life,with high safety.